Novo Nordisk taps board members to join newly acquired Biocorp
Novo Nordisk has become the majority owner of its French partner Biocorp.
Novo Nordisk’s planned acquisition of Biocorp, which has developed a digital add-on device for injection pens, has come a big step closer and the pharmaceutical company can now call itself the majority owner of the former partner.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
.jpg)
